Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: FEBS J. 2013 Apr 8;280(9):10.1111/febs.12226. doi: 10.1111/febs.12226

Fig. 6.

Fig. 6

Inhibition of CSCs by gefitinib in NPC xenografts. (A) Nude mice harboring CNE2 cell xenografts were treated with saline, gefitinib, or cisplatin for 2 weeks as described in Materials and methods. Graphs represent mean volume ± SD (n = 6). P< 0.01. (B and C) Cells dissociated from primary xenografts were subjected to FACS analyses. Percentages of SP cells were significantly decreased by gefitinib and increased by cisplatin. Bar = mean ± SD (n = 3). *, P< 0.01. (D) Immunohistochemical staining of primary tumors from the mouse model. Photographs were taken at ×200 magnification. (E) Cells from primary xenografts were reimplanted into nude mice for development of secondary tumors. Gefitinib abrogated tumor regeneration in secondary mice. Graphs represent mean volume ± SD (n = 6).